Search Results - drug+target

6 Results

Sort By:

Modified Ectodomain of Human EGFR as a Potential Anticancer Agent

Development of a protein that attenuates EGFR and/or EGFR family members and is comprised of a modified EGFR ectodomain. The protein inhibits signaling via the EGFR and/or EGFR family members. The protein includes a portion of the EGFR (or EGFR family member) and the "U" region epitope of EGFR related protein (ERRP), wherein the portion of the EGFR...

Published: 2/6/2014 | Inventor(s): Adhip Majumdar, Arun Rishi, Yingjie Yu

Keywords(s): Breast Cancer, Cancer, Cancer Therapies, Disease, Drug Target, Protein, Therapeutics

Category(s): Life Science, Biologicals, Diseases, Oncology

GlyB4 Fusion with Neuregulin Heparin-Targeting Domain to Block Neuregulin Signaling

We have harnessed this natural targeting ability of NRG by fusing the HBD of NRG to soluble HER4. This fusion protein retains high affinity heparin binding to heparin and to cells that express heparan sulfates resulting in a more potent NRG antagonist. In vivo, it is targeted to peripheral nerve segments where it blocks the activity of NRG as a Schwann...

Published: 2/6/2014 | Inventor(s): Jeffrey Loeb, Qunfang Lee

Keywords(s): Anti-cancer, Biotechnology, Cancer risk, Cancer Therapies, Drug Delivery, Drug Target, Epilepsy

Category(s): Life Science, Drug Delivery, Other

Dual action nanocarrier combining CXCR4 antagonist and polyplex gene delivery for treatment of metastatic cancer and other diseases

Novel bio-reducible polymer compositions which combine the ability to act as a CXCR4 antagonist and simultaneously provide enhanced gene delivery through the formation of inert nanocarrier polyplexes have been developed. As would be expected for biodegradable polymers, the cytotoxicity of these nanocarrier compositions are very low with measured IC50...

Published: 3/31/2014 | Inventor(s): David Oupicky, Jing Li

Keywords(s): Cancer, Cancer Therapies, Compound, Drug Delivery, Drug Target, Formulation, Imaging, Nanomaterials, Pharmaceuticals, Therapeutics

Category(s): Drug Delivery, Gene Therapy, Therapeutics, Life Science, Oncology, Nano-based, Metabolic disorders, Biologicals

DNA Molecule Encoding the B3 Adrenegic Receptor

The B3-Adrenergic receptor protein and DNA which encodes same, vectors containing the DNA, host cells transformed with the vectors and methods of using the protein, the DNA and the transformed host cells. Widely licensed on a non-exclusive basis for diabetes research. U.S. Patent #5,364,772.

Published: 3/31/2014 | Inventor(s): James Granneman, Kristine Lahners, Donald Rao

Keywords(s): Disease, DNA, Drug Target, Therapeutics

Category(s): Drug Screening, Diseases, Life Science, Small molecule, Therapeutics, Metabolic disorders

Derivation of Molecular Targets of Cancer and Aging Using Cellular Immortalization-Specific Gene-Expression

Detailed Description WSU faculty developed an approach to identify gene-expression changes in spontaneously immortalized human cell lines as compared to non-immortal cells. This approach led to the identification of molecular targets required for the long lifespan spontaneously acquired by cancer cells. These targets may provide a potential means...

Published: 3/31/2014 | Inventor(s): Sorin Draghici, Olga Studitskaia, Michael Tainsky

Keywords(s): Cancer, Drug Target

Category(s): Diagnostic, Life Science, Oncology

Novel Mammalian Putative Phosphatidylinositol-4-Phosphate-5-Kinase

Researchers at Wayne State University have discovered a novel mammalian gene which may be involved in membrane trafficking, more specifically, insulin-induced translocation of the fat/muscle-specific glucose transporter GLUT4. This material is a potentially valuable research tool for investigation relating to the diagnosis or therapy of diabetes....

Published: 3/31/2014 | Inventor(s): Assia Shisheva

Keywords(s): DNA, Drug Target, Therapeutics

Category(s): Biotechnology, Diseases, Life Science, Metabolic disorders, Therapeutics